667,632 Shares in Intellia Therapeutics, Inc. (NASDAQ:NTLA) Purchased by Trexquant Investment LP

Trexquant Investment LP acquired a new position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 667,632 shares of the company's stock, valued at approximately $7,785,000. Trexquant Investment LP owned approximately 0.66% of Intellia Therapeutics as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Franklin Resources Inc. boosted its holdings in Intellia Therapeutics by 10.3% in the third quarter. Franklin Resources Inc. now owns 16,405 shares of the company's stock valued at $320,000 after purchasing an additional 1,538 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its position in shares of Intellia Therapeutics by 14.0% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 12,863 shares of the company's stock worth $157,000 after buying an additional 1,582 shares during the last quarter. Arizona State Retirement System boosted its holdings in shares of Intellia Therapeutics by 6.1% in the 4th quarter. Arizona State Retirement System now owns 28,006 shares of the company's stock valued at $327,000 after buying an additional 1,615 shares in the last quarter. E Fund Management Co. Ltd. grew its position in shares of Intellia Therapeutics by 10.0% in the 4th quarter. E Fund Management Co. Ltd. now owns 18,053 shares of the company's stock valued at $210,000 after buying an additional 1,634 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its stake in Intellia Therapeutics by 10.5% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 21,596 shares of the company's stock worth $252,000 after acquiring an additional 2,059 shares in the last quarter. Hedge funds and other institutional investors own 88.77% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on NTLA. Wells Fargo & Company decreased their price objective on shares of Intellia Therapeutics from $60.00 to $50.00 and set an "overweight" rating for the company in a research note on Friday, February 28th. Barclays decreased their target price on Intellia Therapeutics from $55.00 to $26.00 and set an "overweight" rating for the company in a research report on Friday, February 28th. The Goldman Sachs Group reaffirmed a "sell" rating and set a $9.00 price target on shares of Intellia Therapeutics in a research report on Friday, February 28th. Morgan Stanley downgraded Intellia Therapeutics from an "overweight" rating to an "equal weight" rating and decreased their price objective for the company from $56.00 to $11.00 in a report on Monday, January 27th. Finally, StockNews.com raised shares of Intellia Therapeutics to a "sell" rating in a report on Monday, March 3rd. Two research analysts have rated the stock with a sell rating, six have given a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Intellia Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $37.56.

Intellia Therapeutics Stock Performance

Intellia Therapeutics stock traded up $0.80 during midday trading on Wednesday, reaching $7.08. The company's stock had a trading volume of 5,499,886 shares, compared to its average volume of 2,309,210. Intellia Therapeutics, Inc. has a fifty-two week low of $5.90 and a fifty-two week high of $28.18. The firm has a market capitalization of $732.90 million, a PE ratio of -1.30 and a beta of 2.23. The stock's 50 day simple moving average is $9.25 and its 200 day simple moving average is $12.79.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.